Certain phorbol esters, polar solvents and retinoids have been identified as in vitro inducers of human myeloid leukemic cell differentiation. However, the mechanisms by which these diverse classes of agents induce differentiation remain ulcer. Furthermore, it is not clear whether most agents that induce differentiation in vitro exert similar effects in vivo. The proposed studies will address these two related issues. Few insights are presently available regarding the intracellular signaling events activated by inducers of leukemic cell differentiation. However, recent studies have demonstrated that different classes of inducers similarly activate expression of the c-jun and EGR-1 early response genes. The proposed studies will focus on the signaling mechanisms responsible for the induction of myeloid differentiation. The proposed studies will also continue to examine the therapeutic effects of differentiating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. The induction of differentiation in vivo will be assessed by monitoring clonality of leukemic blasts and mature blood cells.
The specific aims are: 1) to determine the involvement of early response genes in signaling events associated with the induction of monocytic differentiation; 2) to further define the role of protein kinase C activity in the differentiation of myeloid leukemia cells; 3) to utilize insertional mutagenesis for the identification of genes involved in the differentiation of myeloid leukemia cells; and 4) to further study the effects of differentiating agents in the therapy of myelodysplastic syndromes and acute myeloid leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042802-08
Application #
2090968
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1986-08-01
Project End
1997-01-31
Budget Start
1994-02-01
Budget End
1995-01-31
Support Year
8
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Jain, Salvia; Stroopinsky, Dina; Yin, Li et al. (2015) Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood 126:354-62
Raina, Deepak; Agarwal, Praveen; Lee, James et al. (2015) Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One 10:e0135156
Yin, Li; Kufe, Turner; Avigan, David et al. (2014) Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood 123:2997-3006
Liu, Suiyang; Yin, Li; Stroopinsky, Dina et al. (2014) MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood 123:734-42
Liu, Yan; Marks, Kevin; Cowley, Glenn S et al. (2013) Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 3:870-9
Stroopinsky, Dina; Rosenblatt, Jacalyn; Ito, Keisuke et al. (2013) MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res 73:5569-79
Jin, C; Rajabi, H; Rodrigo, C M et al. (2013) Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene 32:2179-88
Jin, Caining; Rajabi, Hasan; Pitroda, Sean et al. (2012) Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One 7:e39432
Ahmad, Rehan; Alam, Maroof; Rajabi, Hasan et al. (2012) The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem 287:20866-75
Raina, Deepak; Ahmad, Rehan; Rajabi, Hasan et al. (2012) Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol 40:1643-9

Showing the most recent 10 out of 130 publications